Baseline Tests Before Starting Vascepa
Doctors typically order blood tests to check triglycerides and liver function before prescribing Vascepa (icosapent ethyl), a drug for adults with severe hypertriglyceridemia (triglycerides ≥500 mg/dL) or cardiovascular risk reduction when triglycerides are 150 mg/dL or higher despite statin therapy.[1]
- Triglyceride levels: Fasting blood test to confirm ≥500 mg/dL (for primary indication) or ≥150 mg/dL on statins (for CV risk reduction). Retest if levels are borderline.
- Lipid panel: Full profile including LDL-C, HDL-C, and total cholesterol to assess overall risk and ensure LDL-C isn't elevated (Vascepa doesn't lower LDL-C).
- Liver enzymes (ALT/AST): Baseline to rule out hepatic impairment; Vascepa carries a risk of elevated enzymes.
No routine tests for kidney function or hemoglobin A1c are required unless comorbidities exist, per prescribing guidelines.[1][2]
Why These Tests Matter for Vascepa
High triglycerides must be verified because Vascepa targets this specifically—it's not for general cholesterol lowering. Liver tests monitor for rare elevations (up to 3x ULN in trials). FDA approval requires documented levels to qualify patients.[1]
Tests During Treatment
Monitor triglycerides every 3-6 months until stable, then annually. Check liver enzymes at 3, 6, and 12 months, then periodically. Stop if triglycerides fall below 150 mg/dL without CV indication.[1][2]
What If You Have Diabetes or Other Conditions?
For patients with type 2 diabetes (common in CV risk group), confirm controlled blood sugar via A1c, as Vascepa showed CV benefits here in REDUCE-IT trial. No pancreas-specific tests needed, but screen for pancreatitis history (abdominal pain, amylase/lipase if suspected).[1][3]
Alternatives If Tests Show Issues
If liver enzymes are high, consider statins alone or fibrates like fenofibrate. For triglycerides 200-499 mg/dL, lifestyle changes often precede drugs—no Vascepa without statin optimization.[2]
[1]: Vascepa Prescribing Information (FDA)
[2]: Drugs.com - Vascepa
[3]: REDUCE-IT Trial Summary (NEJM)